Products advanced through the collaboration will be commercialized by Aequus.
The CBRD, Canada's national drug development and commercialization centre, announced a broad research collaboration to establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics targeting neurological movement disorders, including epilepsy, multiple sclerosis, Parkinson's disease and Huntington's disease.
Pipeline included neurology...
Aequus's development stage pipeline includes several products in neurology, so this initiative is right up its street.
It said it has initiated a research program of cannabinoid-based therapeutics targeting neurological disorders.
In Canada, patients have the ability to access cannabis for medical purposes when recommended by their physician, but this field of medicine is still relatively under-research in terms of determining the proper dosage and frequency for patients dealing with a wide variety of symptoms and disease areas.
Aequus recently published a survey that confirms the medical need for improved clinical trial data supporting safety and efficacy of medical cannabis, reliability of dose delivery systems, high quality data collection tracking real world clinical outcomes, physician education, and quality controlled ingredients.
Now it is working with the CDRD to address many of these deficiencies.
The preclinical studies, including in-vitro (test tube) and in-vivo (in humans) toxicology, pharmacology, and formulation optimization in relevant disease models, will be conducted at CDRD's facilities in Vancouver, BC, pending Health Canada approvals.
An exciting step...
"This is an exciting step as we advance toward our goal of providing patients and physicians with clinically validated cannabinoid containing treatments delivered in a more precise and optimized manner than inhaling or ingesting, the most common current methods of delivery," said Doug Janzen, the chairman and chief executive officer (CEO) of Aequus.
"We view the clinician community as being important stakeholders, and we are excited to work with a world class drug research and development organization like CDRD as we strive to provide the medical community with validated and improved alternatives to existing products,” Janzen continued.
“Together our two organizations have proven expertise in taking drugs from discovery and preclinical trials all the way through clinical trials to regulatory launch and commercial sales -- a potent combination for advancing cannabinoid containing therapeutics for neurologic movement disorders," he added.
Meanwhile, Gordon McCauley, president and CEO of the CDRD, said the collaboration with Aequus was a great example of the work the centre does with biotech companies across the country.
“There is a clear unmet medical need in the area of medical cannabinoid research and development where CDRD and Aequus can collaborate and share their respective expertise that could lead to new cannabinoid therapeutics and a pathway to clinical trials, particularly in neurological movement disorders," McCauley said.